Capsugel Acquires GSK’s FlexTab Technology

Capsugel has acquired the FlexTab technology, a dosage form developed by GlaxoSmithKline. The technology uses injection molding processes to produce unique capsule-shaped dosage forms that offer a new platform for formulating a wide range of new products. The FlexTab technology allows for a variety of fill materials, including powders, pellets, liquids, micro-tablets and tablets, and can deliver separate liquid and powder API’s in one dose, allowing for new product designs and customization options.

“Capsugel is very excited to have this innovative technology as part of our suite of offerings,” said Keith Hutchison, vice president of R&D at Capsugel. “We believe that the FlexTab technology’s unique performance characteristics and novel presentation will enable us to formulate the next generation of pharmaceutical and biotech products for our customers. With fewer new drug entities coming to market, our customers are looking for other ways to improve the therapeutic effectiveness of existing API’s for patients and consumers, for example through better patient compliance and convenience.”